29 episodes

As part of the investment process, we have conducted countless CEO and executive interviews, and found this to be an invaluable use of time. We provide The Wall Street Resource, not only to help you leverage your time, but for discovery and a starting point for due diligence.

The Wall Street Resource Wall Street Resource, LLC

    • Investing

As part of the investment process, we have conducted countless CEO and executive interviews, and found this to be an invaluable use of time. We provide The Wall Street Resource, not only to help you leverage your time, but for discovery and a starting point for due diligence.

    Luna Innovations Incorporated (LUNA) Scott Graeff, CEO

    Luna Innovations Incorporated (LUNA) Scott Graeff, CEO

    Luna Innovations Incorporated is a leader in optical technology, providing unique capabilities in high-performance fiber optic-based test products for the telecommunications industry and distributed fiber optic-based sensing for the aerospace and automotive industries. Luna is organized into two business segments, which work closely together to turn ideas into products: a Technology Development segment and a Products and Licensing segment. Luna’s business model is designed to accelerate the process of bringing new and innovative technologies to market.


    Scott Graeff, CEO

    • 32 min
    Kontrol Energy Corp. (CSE:KNR, OTCQB:KNRLF) Paul Ghezzi, CEO

    Kontrol Energy Corp. (CSE:KNR, OTCQB:KNRLF) Paul Ghezzi, CEO

    Kontrol Energy Corp. is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions for their customers, designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.


    Paul Ghezzi, CEO 

    • 23 min
    Anixa Biosciences, Inc. (ANIX) Dr. Amit Kumar PhD, CEO

    Anixa Biosciences, Inc. (ANIX) Dr. Amit Kumar PhD, CEO

    Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.


    Dr. Amit Kumar PhD, CEO

    • 32 min
    Calyxt, Inc. (CLXT) James Blome, CEO

    Calyxt, Inc. (CLXT) James Blome, CEO

    Calyxt (NASDAQ: CLXT), based in Roseville, Minnesota, is a plant-based technology company that utilizes our patented breeding technology to make the food you love a healthier choice. The care we take extends beyond nutritional value. We partner with farmers and food companies to deliver traceable plant-based products developed to be healthier and more sustainable than their conventional counterparts. We use cutting edge plant breeding techniques to develop products that help improve diets by reducing bad fats, allergens and toxins. Today oil from our high oleic soybean plants has lower saturated fats than commodity soybean oil. We are also developing high fiber wheat designed to provide an excellent source of daily fiber when incorporated into wheat-based foods. We continuously pursue innovation to deliver good food that is good for you.


    James Blome, CEO

    • 22 min
    Equillium, Inc. (EQ) Bruce Steel, CEO

    Equillium, Inc. (EQ) Bruce Steel, CEO

    Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium’s initial product candidate, itolizumab (EQ001), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab is a clinically-validated therapeutic that has demonstrated a favorable safety and tolerability profile.


    Bruce Steel, CEO

    • 19 min
    One Stop Systems, Inc. (OSS) Steve Cooper, CEO

    One Stop Systems, Inc. (OSS) Steve Cooper, CEO

    One Stop Systems, Inc. (OSS) designs and manufactures innovative specialized high-performance computing building blocks and platforms for OEMs that provide edge systems to scientists, engineers, creators and other professionals for their mission critical applications. These specialized platforms include customized servers, compute accelerators, flash storage arrays, expansion systems and storage software. The products are used for deep learning, AI, defense, finance and entertainment applications.


    Steve Cooper, CEO

    • 25 min

Customer Reviews

Karmaman805 ,

Informative

Quick & to the point! No fluff, straight up info.

LK2500 ,

Very useful podcasts

Excellent and informative podcasts. You quickly get vital company data from key personnel. Highly recommended.

Top Podcasts In Investing